메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Moore Global Named Network of the Year in Unanimous Decision

Award comes after four consecutive years of double-digit growth LONDON, July 10, 2025 -- Moore Global, the global accounting, audit, and advisory network, was named Network of the Year at the International Accounting Forum and Awards 2025 (IAFA 25) in a unanimous decision by the judges. Vivienne Muir, Moore Global chief operating officer, was presented the prestigious award on June 28 at the IAFA 25 ceremony in London. Vivienne said: "This award is recognition of the quality, dedication, and collaboration that defines our global network. It reflects the ou
- 기자
- 2025-07-10 04:58
Samsung Galaxy Watch8 series: Ultra Comfort, from Sleep to Workout

[ 메디채널 기자 ] Galaxy Watch8 and Galaxy Watch8 Classic merge an iconic design with new, personalised wellness insights to motivate you on your health journey SYDNEY, July 10, 2025 -- Samsung Electronics Co., Ltd. today introduced Galaxy Watch8 and Galaxy Watch8 Classic[1], establishing an iconic design identity across the entire Galaxy Watch line-up. Building upon the foundation of the Galaxy Watch Ultra's cushion design, this series boasts the thinnest, most comfortable Galaxy Watch ever[2] for continuous health tracking. The Galaxy Watch8 series suits diverse lifestyles and provid
- 기자
- 2025-07-10 03:00
Zhimeng Biopharma's Next-Generation KCNQ2/3 Potassium Channel Opener Receives Clinical Trial Approval for ALS Phase 2/3 Study

SHANGHAI, July 10, 2025 -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma"), a clinical-stage biopharmaceutical company dedicated to innovative drug development for liver and central nervous system (CNS) diseases, today announced that its self-discovered next-generation KCNQ2/3 potassium channel opener, CB03-154, has received an approval from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to initiate a Phase 2/3 clinical study in China for amyotrophic lateral sclerosis (ALS, also known as "Lou Gehrig's disease"). Previ
- 기자
- 2025-07-10 00:00
LBB Specialties Expands Distribution Partnership with Clariant to Support Puerto Rico's Life Sciences Market

NORWALK, Conn., July 9, 2025 -- LBB Specialties (LBBS), a leader in specialty chemicals and ingredient distribution in North America, is pleased to announce the expansion of its distribution partnership with Clariant, a global leader in the development and manufacturing of specialty chemical solutions. This expansion enhances LBBS's presence in Puerto Rico's robust Life Sciences sector, providing customers with local access to Clariant's pharmaceutical-grade excipients, including the VitiPure™ product line. Under this expanded agreement, LBB Specialties will now support the Pue
- 기자
- 2025-07-09 23:00
NYSE Content advisory: Pre-Market update + Trump announces 50% levy on copper imports

NEW YORK, July 9, 2025 -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content advisory: Pre-Market update + Trump announces 50% levy on copper imports Kristen Scholer delivers the pre-market update on July 9th President Trump announced 50% levy on copper imports on Tuesday President Trump also hinted at implementing up to a 200% tariff on pharmaceutical imports Investors are awaiting today's Fed Minu
- 기자
- 2025-07-09 20:55
GenScript Biotech Earns EcoVadis Silver Medal, Ranking in Top 15% Globally for Sustainability

PISCATAWAY, N.J., July 9, 2025 -- GenScript Biotech Corporation (HK.1548), a leading global provider of life science research and manufacturing services, today announced that it has been awarded a Silver Medal by EcoVadis, a globally recognized business sustainability assessment platform. This recognition underscores its significant progress in the areas of environment, labor and human rights, ethics, and sustainable procurement. This silver medal places GenScript in the top 15% of all companies assessed by EcoVadis worldwide. In the latest reassessment, GenScript outperforms 85% of co
- 기자
- 2025-07-09 20:32
IASO Bio Receives Orphan Drug Designation from the Ministry of Food and Drug Safety of South Korea for Equecabtagene Autoleucel

[ 메디채널 기자 ] SHANGHAI, NANJING, China and SAN FRANCISCO, July 9, 2025 -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that its self-developed anti-BCMA CAR-T cell therapy product, Equecabtagene Autoleucel (Fucaso), has been granted Orphan Drug Designation (ODD) by the Ministry of Food and Drug Safety (MFDS) of South Korea for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM) who have received a
- 기자
- 2025-07-09 20:18
GENAI Summit 2025: Forging a Network of AI Innovators

HONG KONG, July 9, 2025 -- The GENAI Summit Hong Kong is designed to foster collaboration and knowledge-sharing, offering a dynamic platform for attendees to dive into the practical applications of GenAI in industries such as finance, healthcare, marketing, education, and entertainment. With an expected attendance of over 500+ participants and representatives from leading gen AI tech companies, the event promises to be a landmark moment for Hong Kong's growing role as a global GEN AI hub. The summit will feature a packed agenda, including: Keynote Addresses: Visionary leader
- 기자
- 2025-07-09 20:02
Sironax Grants Novartis Exclusive Option to Acquire its Brain Delivery Platform While Retaining Rights to Advance Selected Therapeutic Assets

WALTHAM, Mass., July 9, 2025 -- Sironax, a clinical-stage biotech company dedicated to the discovery and development of transformational therapies for age-related diseases, today announced a strategic agreement with Novartis under which Sironax will grant Novartis an exclusive option to acquire its proprietary Brain Delivery Module (BDM) platform, a differentiated blood-brain-barrier (BBB) crossing technology designed to enhance the brain delivery of therapeutics of various modalities. Sironax retains the right to continue developing selected therapeutic assets using the platform. &q
- 기자
- 2025-07-09 20:00
Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial

SYDNEY, July 9, 2025 -- Kazia Therapeutics (NASDAQ: KZIA) is pleased to announce preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, pembrolizumab (Keytruda®), and standard chemotherapy after completing Cycle 1 (21 days) of dosing. The patient, a 61-year-old woman with metastatic triple-negative breast cancer localized to the left upper lobe of the lung, has shown highly encouraging preliminary results at 21 days, with a >50% reduction in circulating tumor cells (CTCs) and a notable decrease in CTC clusters. The early d
- 기자
- 2025-07-09 20:00

이전

51 52 53 54 55 56 57 58 59 60

많이 본 기사

최근기사

2025-09-09_TUE

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 09일 10시 40분